Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06320444Recruiting

Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease

Role: collaborator

NCT05663008Recruiting

Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis

Role: collaborator

NCT04918251Unknown

EEG and TMS-based Biomarkers of ALS, MS and FTD

Role: collaborator

All 3 trials loaded